Ali-Boucetta, Hanene

English

Carbon-based nanomaterials have attracted a lot of attention in recent years because of their unique and extraordinary properties which could be exploited for therapeutic, diagnostic and theranostic purposes. Functionalized Carbon Nanotubes (ƒCNTs) have shown their ability to deliver therapeutic molecules ranging from small anticancer molecules to macromolecules as they are up taken by cells via an energy independent mechanism. While chemotherapy is still the main therapeutic modality in the treatment of cancer, there is always the issue of side effects and relapse after treatment. ƒCNTs can be engineered to specifically target cancer cells, increase the drug payload inside them and reduce multidrug resistance. Carbon nanotubes can therefore act as anticancer Trojan horses. Herein, the discussion is on the state of the art of ƒCNTs as cancer therapeutics and their potential for the delivery of cancer therapeutics in 2D cell monolayers, 3D tumor spheroids and in vivo models. The further highlight is on the gaps in the field which needs to be addressed before the translational move of these nanomaterials into the clinic

University of Birmingham Research Portal

  University of BirminghamCarbon-based nanomedicines as anticancer TrojanHorsesAli-Boucetta, HaneneDOI:10.4172/2324-8777-C5-031License:None: All rights reservedDocument VersionPublisher's PDF, also known as Version of recordCitation for published version (Harvard):Ali-Boucetta, H 2018, 'Carbon-based nanomedicines as anticancer Trojan Horses', International Conference onNanomedicine and Nanotechnology 2018, Rome, Italy, 20/08/18. https://doi.org/10.4172/2324-8777-C5-031Link to publication on Research at Birmingham portalPublisher Rights Statement:Ali-Boucetta, H 2018, 'Carbon-based nanomedicines as anticancer Trojan Horses' International Conference on Nanomedicine andNanotechnology 2018, Rome, Italy, 20/08/18, .DOI : 10.4172/2324-8777-C5-031General rightsUnless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or thecopyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposespermitted by law.•	Users may freely distribute the URL that is used to identify this publication.•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of privatestudy or non-commercial research.•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)•	Users may not further distribute the material nor use it for the purposes of commercial gain.Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.When citing, please reference the published version.Take down policyWhile the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has beenuploaded in error or has been deemed to be commercially or otherwise sensitive.If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access tothe work immediately and investigate.Download date: 01. Mar. 2020Volume 7Journal of Nanomaterials & Molecular Nanotechnology Nanomedicine 2018August 20-21, 2018Page 15Nanomedicine and NanotechnologyAugust 20-21, 2018   Rome, ItalyInternational Conference onNotes:Hanene Ali-Boucetta, J Nanomater Mol Nanotechnol 2018, Volume 7DOI: 10.4172/2324-8777-C5-031Carbon-based nanomedicines as anticancer Trojan HorsesCarbon-based nanomaterials have attracted a lot of attention in recent years because of their unique and extraordinary properties which could be exploited for therapeutic, diagnostic and theranostic purposes. Functionalized Carbon Nanotubes (ƒCNTs) have shown their ability to deliver therapeutic molecules ranging from small anticancer molecules to macromolecules as they are up taken by cells via an energy independent mechanism. While chemotherapy is still the main therapeutic modality in the treatment of cancer, there is always the issue of side effects and relapse after treatment. ƒCNTs can be engineered to specifically target cancer cells, increase the drug payload inside them and reduce multidrug resistance. Carbon nanotubes can therefore act as anticancer Trojan horses. Herein, the discussion is on the state of the art of ƒCNTs as cancer therapeutics and their potential for the delivery of cancer therapeutics in 2D cell monolayers, 3D tumor spheroids and in vivo models. The further highlight is on the gaps in the field which needs to be addressed before the translational move of these nanomaterials into the clinic.BiographyHanene Ali-Boucetta has completed her Master of Pharmacy degree from UCL School of Pharmacy. He has pursued her PhD at Nanomedicine Laboratory at UCL School of Pharmacy investigating the pharmacokinetics and toxicology of carbon nanotubes and their development into effective nano-vectors for cancer therapeutics under the supervision of Kostas Kostarelos. She was awarded the prestigious C W Maplethorpe Research and Teaching Postdoctoral Fellowship from the University of London. She has joined the School of Pharmacy at University of Birmingham as a Lecturer in Pharmaceutical Nanoscience. She is leading the Nanomedicine and Drug Delivery Laboratory and her team is working on the development of novel nano-delivery systems for the treatment of cancer, neurodegenerative disorders and microbial infections. She has published numerous peer-reviewed articles, reviews and book chapters.h.aliboucetta@bham.ac.ukHanene Ali-BoucettaUniversity of Birmingham, UK

Carbon-based nanomedicines as anticancer Trojan Horses

  Carbon-based nanomedicines as anticancer TrojanHorsesAli-Boucetta, HaneneDOI:10.4172/2324-8777-C5-031License:None: All rights reservedDocument VersionPublisher's PDF, also known as Version of recordCitation for published version (Harvard):Ali-Boucetta, H 2018, 'Carbon-based nanomedicines as anticancer Trojan Horses' International Conference onNanomedicine and Nanotechnology 2018, Rome, Italy, 20/08/18, . https://doi.org/10.4172/2324-8777-C5-031Link to publication on Research at Birmingham portalPublisher Rights Statement:Ali-Boucetta, H 2018, 'Carbon-based nanomedicines as anticancer Trojan Horses' International Conference on Nanomedicine andNanotechnology 2018, Rome, Italy, 20/08/18, .DOI : 10.4172/2324-8777-C5-031General rightsUnless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or thecopyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposespermitted by law.•	Users may freely distribute the URL that is used to identify this publication.•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of privatestudy or non-commercial research.•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)•	Users may not further distribute the material nor use it for the purposes of commercial gain.Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.When citing, please reference the published version.Take down policyWhile the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has beenuploaded in error or has been deemed to be commercially or otherwise sensitive.If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access tothe work immediately and investigate.Download date: 01. Feb. 2019Volume 7Journal of Nanomaterials & Molecular Nanotechnology Nanomedicine 2018August 20-21, 2018Page 15Nanomedicine and NanotechnologyAugust 20-21, 2018   Rome, ItalyInternational Conference onNotes:Hanene Ali-Boucetta, J Nanomater Mol Nanotechnol 2018, Volume 7DOI: 10.4172/2324-8777-C5-031Carbon-based nanomedicines as anticancer Trojan HorsesCarbon-based nanomaterials have attracted a lot of attention in recent years because of their unique and extraordinary properties which could be exploited for therapeutic, diagnostic and theranostic purposes. Functionalized Carbon Nanotubes (ƒCNTs) have shown their ability to deliver therapeutic molecules ranging from small anticancer molecules to macromolecules as they are up taken by cells via an energy independent mechanism. While chemotherapy is still the main therapeutic modality in the treatment of cancer, there is always the issue of side effects and relapse after treatment. ƒCNTs can be engineered to specifically target cancer cells, increase the drug payload inside them and reduce multidrug resistance. Carbon nanotubes can therefore act as anticancer Trojan horses. Herein, the discussion is on the state of the art of ƒCNTs as cancer therapeutics and their potential for the delivery of cancer therapeutics in 2D cell monolayers, 3D tumor spheroids and in vivo models. The further highlight is on the gaps in the field which needs to be addressed before the translational move of these nanomaterials into the clinic.BiographyHanene Ali-Boucetta has completed her Master of Pharmacy degree from UCL School of Pharmacy. He has pursued her PhD at Nanomedicine Laboratory at UCL School of Pharmacy investigating the pharmacokinetics and toxicology of carbon nanotubes and their development into effective nano-vectors for cancer therapeutics under the supervision of Kostas Kostarelos. She was awarded the prestigious C W Maplethorpe Research and Teaching Postdoctoral Fellowship from the University of London. She has joined the School of Pharmacy at University of Birmingham as a Lecturer in Pharmaceutical Nanoscience. She is leading the Nanomedicine and Drug Delivery Laboratory and her team is working on the development of novel nano-delivery systems for the treatment of cancer, neurodegenerative disorders and microbial infections. She has published numerous peer-reviewed articles, reviews and book chapters.h.aliboucetta@bham.ac.ukHanene Ali-BoucettaUniversity of Birmingham, UK

http://pure-oai.bham.ac.uk/ws/files/55052155/Nanomedicine_Conference_Rome_2018.pdf

Carbon-based nanomedicines as anticancer Trojan Horses

Abstract

Similar works

Full text

Available Versions

University of Birmingham Research Portal

University of Birmingham Research Portal